109 related articles for article (PubMed ID: 8928637)
1. Effect of intravenously applied canrenoate on ampullar endolymphatic potential.
Yura K; Mori N; Nario K; Sakai S
Acta Otolaryngol; 1995 Sep; 115(5):648-52. PubMed ID: 8928637
[TBL] [Abstract][Full Text] [Related]
2. Effect of aldosterone antagonist on the DC potential in the endolymphatic sac.
Mori N; Yura K; Uozumi N; Sakai S
Ann Otol Rhinol Laryngol; 1991 Jan; 100(1):72-5. PubMed ID: 1985530
[TBL] [Abstract][Full Text] [Related]
3. Effects of canrenoate potassium, an aldosterone antagonist on portal hemodynamics in patients with compensated liver cirrhosis.
Koda M; Murawaki Y; Kawasaki H; Ikawa S
Hepatogastroenterology; 1996; 43(10):887-92. PubMed ID: 8884309
[TBL] [Abstract][Full Text] [Related]
4. Effects of the aldosterone receptor antagonist potassium canrenoate on renal blood flow and urinary output during prolonged increased intraabdominal pressure (IAP) in pigs.
Gudmundsson FF; Viste A; Myking OL; Grong K; Svanes K
Surg Endosc; 2004 Oct; 18(10):1528-34. PubMed ID: 15791383
[TBL] [Abstract][Full Text] [Related]
5. Origin of the endolymphatic DC potential in the cochlea and ampulla of the guinea pig.
Ono T; Tachibana M
Eur Arch Otorhinolaryngol; 1990; 248(2):99-101. PubMed ID: 2282222
[TBL] [Abstract][Full Text] [Related]
6. Comparative effects of canrenoate-K and prorenoate-K upon aldosterone biosynthesis in perifused frog interrenal glands.
Delarue C; Leboulenger F; Tonon MC; Jegou S; Leroux P; Kusmierek MC; Corvol P; Vaillant R; Vaudry H
Steroids; 1979 Sep; 34(3):319-32. PubMed ID: 494369
[TBL] [Abstract][Full Text] [Related]
7. Mineralocorticoid receptor blockade by canrenoate increases both spontaneous and stimulated adrenal function in humans.
Arvat E; Maccagno B; Giordano R; Pellegrino M; Broglio F; Gianotti L; Maccario M; Camanni F; Ghigo E
J Clin Endocrinol Metab; 2001 Jul; 86(7):3176-81. PubMed ID: 11443185
[TBL] [Abstract][Full Text] [Related]
8. The difference in endocochlear and endolymphatic sac d.c. potentials in response to furosemide and canrenoate as diuretics.
Mori N; Uozumi N; Yura K; Sakai S
Eur Arch Otorhinolaryngol; 1990; 247(6):371-3. PubMed ID: 2278704
[TBL] [Abstract][Full Text] [Related]
9. Negative inotropic effects of aldosterone antagonists in isolated human and guinea-pig ventricular heart muscle.
Mügge A; Schmitz W; Scholz H
Klin Wochenschr; 1984 Aug; 62(15):717-23. PubMed ID: 6492693
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist.
Bos R; Mougenot N; Findji L; Médiani O; Vanhoutte PM; Lechat P
J Cardiovasc Pharmacol; 2005 Jan; 45(1):8-13. PubMed ID: 15613973
[TBL] [Abstract][Full Text] [Related]
11. [Effect of potassium canrenoate on the EP and Na+, K+ activities in endolymph].
Wakizono S; Komune S; Hisashi K; Uemura T
Nihon Jibiinkoka Gakkai Kaiho; 1990 Mar; 93(3):373-80. PubMed ID: 2352044
[TBL] [Abstract][Full Text] [Related]
12. Decreased vasopressin-mediated renal water reabsorption in rats with chronic aldosterone-receptor blockade.
Jonassen TE; Promeneur D; Christensen S; Petersen JS; Nielsen S
Am J Physiol Renal Physiol; 2000 Feb; 278(2):F246-56. PubMed ID: 10662729
[TBL] [Abstract][Full Text] [Related]
13. Intravenous Mineralocorticoid Receptor Antagonist Use in Acutely Decompensated Heart Failure with Diuretic Resistance.
Girerd N; Aubry M; Lantelme P; Huttin O; Rossignol P
Int Heart J; 2021 Jan; 62(1):193-196. PubMed ID: 33455988
[TBL] [Abstract][Full Text] [Related]
14. Improved method for comparative evaluation of aldosterone antagonists in healthy man.
Casals-Stenzel J; Schmalbach J; Losert W
Eur J Clin Pharmacol; 1977 Dec; 12(4):247-55. PubMed ID: 590311
[TBL] [Abstract][Full Text] [Related]
15. Differential impacts of mineralocorticoid receptor antagonist potassium canrenoate on liver and renal changes in high fat diet-mediated early hepatocarcinogenesis model rats.
Nakamura M; Eguchi A; Inohana M; Nagahara R; Murayama H; Kawashima M; Mizukami S; Koyanagi M; Hayashi SM; Maronpot RR; Shibutani M; Yoshida T
J Toxicol Sci; 2018; 43(10):611-621. PubMed ID: 30298849
[TBL] [Abstract][Full Text] [Related]
16. Fadrozole reverses cardiac fibrosis in spontaneously hypertensive heart failure rats: discordant enantioselectivity versus reduction of plasma aldosterone.
Minnaard-Huiban M; Emmen JM; Roumen L; Beugels IP; Cohuet GM; van Essen H; Ruijters E; Pieterse K; Hilbers PA; Ottenheijm HC; Plate R; de Gooyer ME; Smits JF; Hermans JJ
Endocrinology; 2008 Jan; 149(1):28-31. PubMed ID: 17884944
[TBL] [Abstract][Full Text] [Related]
17. [Effect of furosemide on the ampullar endolymphatic potential and endolymphatic Ca2+ activity].
He D; Zhou W; Chen Z
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 1997 Sep; 11(9):392-5. PubMed ID: 10323004
[TBL] [Abstract][Full Text] [Related]
18. Detection and comparative evaluation of aldosterone antagonists in glucocorticoid-treated, adrenalectomized rats.
Casals-Stenzel J; Buse M; Losert W
Eur J Pharmacol; 1982 May; 80(1):37-45. PubMed ID: 7095004
[TBL] [Abstract][Full Text] [Related]
19. Effect of aldosterone on potassium excretion during potassium chloride infusion in sheep.
Rabinowitz L; Sarason RL; Yamauchi H
Am J Physiol; 1985 Oct; 249(4 Pt 2):R455-61. PubMed ID: 4051031
[TBL] [Abstract][Full Text] [Related]
20. Patients with acute heart failure treated with the CARRESS-HF diuretic protocol in association with canrenoate potassium: Tolerance of high doses of canrenoate potassium.
Berger C; Prieur C; Bochaton T; Berthiller J; Luyt CE; Bonnefoy-Cudraz E
Arch Cardiovasc Dis; 2020 Nov; 113(11):679-689. PubMed ID: 32948466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
